

1 PATIENT INFORMATION Patient Name: _____ Phone: _____ Address: _____ City: _____ State: _____ Zip: _____ MRN #: _____ DOB: _____ Drug Allergies: _____	2 PRESCRIBER INFORMATION Prescriber's Name: _____ DEA#: _____ NPI: _____ Clinic/Facility Name: _____ Address: _____ City: _____ State: _____ ZIP: _____ Phone: _____ Fax: _____
3 Instructions to Provider All orders with ✓ will be placed unless otherwise noted. Please fax completed order form to 206-326-2139. For drug prior authorization, call 1-888-767-4670 or visit https://wa-provider.kaiserpermanente.org/provider-manual/clinical-review/preservice . Prescribers must be specially certified in the Soliris REMS program and comply with instructions for use.	
4 CLINICAL INFORMATION Diagnosis (ICD-10 code): _____ Date of Last Dose: _____	
5 EPYSQLI PRESCRIPTION INFORMATION Eculizumab-aagh (Epysqli) in 0.9% Sodium Chloride Injection, USP, dilute to a final concentration of 5 mg/mL First Dose: ☐ No ☐ Yes Weight: _____ kg Date Recorded: _____ Dose: ☐ 900 mg ☐ 1200 mg ☐ Other _____ mg Route: Intravenous Frequency: ☐ Every 2 weeks ☐ Other _____ (wk) Refills: ☐ 11 months ☐ Other _____ Infusion Access: ☐ PIV ☐ CVAD ☐ Other: _____ Patient's Current Home Care/Specialty Pharmacy: _____	
Infusion Reaction Medications & Supplies ✓ Hydrocortisone sodium succinate injectable 100 mg IV Sig: Once PRN for hypersensitivity ✓ Epinephrine Auto-Injector ☐ 0.15mg ☐ 0.3mg QTY: 2 Sig: Inject into lateral thigh muscle for severe allergic reaction. Seek medical attention after use. ✓ Sodium Chloride 0.9% IV Flush: Flush 10 ml IV before/after medication administration or as needed for line maintenance ✓ Diphenhydramine injectable 25 mg IV Sig: Once PRN, may repeat x1 for urticaria, pruritis, shortness of breath ✓ Sodium Chloride 0.9% IV 250ml Bag Sig: Once PRN for anaphylaxis	
Labs /Special Instructions/Pre-Meds: _____ _____ _____	
Infusion Protocol: • Infuse per manufacturer guidelines • Monitor vital signs (Temp, BP, HR, RR) every 15 minutes x 4; then every 30 minutes x2; then every 60 minutes until completion of infusion • Documentation must include: ○ Start and end time of infusion ○ All rate changes, vital signs, including initial and final set ○ Patient response	• Observe patient for signs of infusion rate-related adverse reactions: ○ Blood pressure changes, increased pulse rate ○ Fever, chills ○ Headache ○ Chest, back or hip pain ○ Dyspnea ○ Mild erythema
6 PHYSICIAN SIGNATURE REQUIRED	
X _____ SUBSTITUTION PERMITTED (Date)	X _____ DISPENSE AS WRITTEN (Date)

CONFIDENTIALITY NOTICE: This message and any attached files might contain confidential information protected by federal and state law. The information is intended only for the use of the individual(s) or entities originally named as addressees. The improper disclosure of such information may be subject to civil or criminal penalties. If this message reached you in error, please contact the sender and destroy this message. Disclosing, copying, forwarding, or distributing the information by unauthorized individuals or entities is strictly prohibited by law.

Members with Medicare Part B or D coverage are not required to use this form.